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Objectives
 List the characteristic features of the 
arthritis of Rheumatoid Arthritis
 List the extraarticular features of 
Rheumatoid Arthritis & their risk 
factors
 Know when to refer to consultants
 List the key components in the 
treatment of Rheumatoid Arthritis
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Outline
 Review definition and articular 
features of Rheumatoid Arthritis
 Describe extraarticular 
manifestations of Rheumatoid 
Arthritis
 Review goals and strategies for 
Rheumatoid Arthritis treatment
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Review definition and 
articular features of 
Rheumatoid Arthritis
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Rheumatoid Arthritis: Definition
Severe, common 
inflammatory disorder 
characterized by chronic 
polyarthritis and systemic 
manifestations
 
Prevalence of ~ 1% in Caucasians of northern European 
ancestry. Affects all age groups, females > males. 
2010 ACR/EULAR criteria for diagnosis included in 
Supplement. 
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Slide 7 What are the articular features of 
RA?
 Chronic polyarthritis
– Inflammatory
–Symmetric
–Small and large joint involvement
–Upper cervical spine involvement; 
not lower back
–Potentially any synovial joint
–May develop into destructive 
arthritis
 
Chronic arthritis – complaints > 6 weeks of duration 
(insidious onset) with warm/swollen/tender joints; not 
erythematous/hot/excruciatingly tender joints of acute 
arthritis. 
 
Reminder: inflammatory arthritis is defined by history  - 
pain that is worse after immobility, typically in AM; 
improves with gentle activity, worsens with rest; 
associated significant AM stiffness (> 1 hr). 
 
Distribution in hands: MCPs/PIPs; in feet: MTPs/PIPs; 
wrists. 
 
Destructive arthritis = joint subluxation & erosive disease 
on x-rays (see Supplement) 
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Polyarthritis in RA: Early Disease
 
What joints are involved? 
 
Early disease is < 6 months duration.  
 
See Supplement for additional information on polyarthritis 
of RA (photo of advanced disease, pathophysiology, x-
rays of erosive disease) 
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What are the atypical presentations 
of RA? *
 Intermittent or migratory 
(pallindromic rheumatism)
 Acute fulminant polyarthritis –
especially in the elderly
 Monoarthritis
 PMR-like
 Extraarticular manifestation - rare
 
* Arrow indicates decreasing prevalence. 
 
Pallindromic rheumatism = mono- or oligoarthritis arises 
abruptly, lasts for hours – days, recurs often at a different 
location; 30-60% will progress to RA, especially if 
rheumatoid factor and anti-CCP – positive; response to 
anti-malarials suggests will develop into RA 
 
Monoarticular = may develop after trauma to that joint, 
usually develops polyarthritis within weeks to months 
 
PMR- like = early on “myalgic” in same distribution as 
PMR, then develops typical RA distribution; slower 
response to steroids than PMR 
 
Extraarticular manifestations eg nodules & episcleritis, 
others less likely 
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10 KEY POINTS
Articular Features of RA
 Common
 Chronic inflammatory POLYarthritis
 Predilection for PROXIMAL SMALL 
JOINTS HANDS/FEET, WRISTS, upper 
neck
 Atypical presentations occur -
uncommon
 May develop into destructive arthritis if 
not managed early & aggressively
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Describe extraarticular 
manifestations of 
Rheumatoid Arthritis
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12 What are the most common 
extraarticular manifestations of RA?
 Constitutional symptoms
 Osteopenia
 Muscle weakness
 Cardiovascular disease (non-vasculitic)
 Rheumatoid nodules
 Pulmonary disease
 Secondary Sjögren's syndrome 
 Vasculitis
 Neutropenia
 Nervous system involvement
 
All of these may be involved as will be discussed on the 
next set of slides. 
 
May occur in up to 40% of patients (top 3 may occur more 
often). Associated with increased overall morbidity & 
premature mortality, & therefore, extraarticular 
manifestations are a marker of severe disease. 
 
Generally, these extraarticular manifestations occur in 
individuals who are older, with poorly controlled, long-
standing disease who smoke & have high levels of RF and 
anti-CCP. 
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13 Constitutional Symptoms
Fatigue
Low grade temperature
Weight loss
AM stiffness
 
Constitutional symptoms are exception – these can occur 
at disease presentation & with flares. 
 
Temperature elevation is low grade; if > 101o consider 
Still’s disease, infection or another diagnosis, ie 
SLE/vasculitis. 
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 Localized to joint
 Generalized
 Periodontal bone loss
 May arise from inflammatory 
process / immobilization / 
treatment with steroids
 
Osteopenia localized to joint  is typically due to 
periarticular demineralization, which is a characteristic 
feature of RA. 
 
Osteoporosis is common. Those with erosive disease, 
may have earlier bone loss.  
 
Increased risk of osteoporotic fracture: major osteoporotic 
fracture increased 30% & hip fracture increased 40%. 
Higher risk of stress fractures, esp fibular – not related to 
trauma. Need to evaluate any new acute & severe bone 
pain. 
 
Need to diagnose osteoporosis early, and treat 
aggressively: use DEXA & FRAX tool. 
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15 Muscle Weakness
 Atrophy resulting from synovitis
 Myositis
 Neuropathy 
– Vasculitis
– Nerve entrapment
 Drug-induced myopathy
– Steroids (uncommon < 10 mg qd)
– Anti-malarials
– Lipid-lowering drugs
 
Myositis usually low grade with biopsy evidence of 
sporadic lymphocytic infiltrates – rarely develops into full 
blown polymyositis 
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16 Non-vasculitic Cardiovascular 
Disease
 Independent risk factor 
– Cardiac diseases
• Coronary artery disease
• Heart failure
• Atrial fibrillation
– Peripheral vascular disease
– Cerebral vascular disease
 Increased risk of sudden death & MI 
 Increased prevalence in those with 
more systemic disease, greater disease 
activity & longer duration of disease
 
Gabriel SE. Heart disease & rheumatoid arthritis: 
understanding the risks. 2010. Ann Rheum Dis 69 Suppl 
1:i61 
Lindhardsen J, et al. Risk of atrial fibrillation & stroke in 
rheumatoid arthritis: Danish nationwide cohort study. 
2012. BMJ 344:e1257 
Turesson C, et al. Severe extra-articular disease 
manifestations are associated with an increased risk of 
first ever cardiovascular events in patients with 
rheumatoid arthritis. 2007. Ann Rheum Dis 66 (1):70. 
 
Important to control other risk factors for these 
diseases! 
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Rheumatoid 
Nodules
 
Most common cutaneous manifestation of RA (20-35% of 
pts). These are firm, flesh colored, usually mobile. Can be 
affixed to bone, but usually subcutaneous at pressure 
points & on extensor surfaces. Typically, not as hard as 
tophi, which may be white-cream colored but may occur at 
same locations. Treatment not indicated unless painful; 
can then use steroid injection. 
 
Presence is predictor of more severe articular disease & 
other extraarticular manifestations, eg Felty’s & vasculitis. 
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18 Rheumatoid Nodule Pathology
 
H & E stains of an early (< 6 months, left panel) vs late 
(right panel) rheumatoid nodule. Small vessel vasculitis 
with necrosis seen early. Palisading histiocytes & central 
necrosis seen late. 
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Pulmonary Manifestations*
 Interstitial lung 
disease / Organizing 
pneumonia (BOOP)
 Pleural effusions / 
pleurisy
 Rheumatoid nodules
 
* Arrow signifies decreasing prevalence. Prevalence 
difficulty to estimate. Much more common than cardiac 
manifestations. 
 
ILD most common esp in smokers; looks like idiopathic 
interstitial pneumonias; usually insidious onset, basilar 
fibrosis. Organizing pneumonia symptomatic – cough, 
fever, dyspnea, weight loss, fever. Need to consider 
infection/drug toxicity/malignancy in the differential 
for both. 
 
Pleural effusions next most common; typically 
asymptomatic & identified on exam or CXR (different than 
those seen in SLE, which tend to be symptomatic). 
Thoracentesis required. Characteristics: exudative - very 
low glucose, high LDH, pH<7.3, WBC<5000 
 
Rh nodules in all sizes – need to consider 
infection/malignancy 
 
NEED TO GET PULMONARY INVOLVED to eliminate 
other causes. 
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20 Secondary Sjögren's 
Syndrome
Keratoconjunctivitis sicca
Xerostomia
 
Occurs in 10-20% of patients. RA is most common cause 
of secondary SS. Usually mild & with sicca complaints 
only. Rare to have extraglandular disease typical of 
primary SS. 
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21 Vasculitis
 Skin
– Rheumatoid nodules
– Digital infarcts
– Leg ulceration
 Eye
– Scleromalacia perforans
 Nervous system
– Neuropathies
 
POTENTIALLY SERIOUS COMPLICATION! Vasculitis 
may affect small vessels (rh nodules) to medium sized 
arteries (PAN-like). 
 
Has predilection for these organ systems. May affect other 
organ systems but much less likely (pericardium, bowel, 
lungs). 
 
Often occurs when arthritis is “burned out” (inactive).  
 
Suspect when worsening constitutional symptoms in 
absence of infection – patient with failure to thrive, 
weight loss, unexplained increased inflammatory 
markers or fever. 
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22 
Cutaneous 
Vasculitis
 
What do you see in each panel? 
 
Top: Digital infarcts (nailfold infarcts are common & 
benign) 
Bottom: Digital gangrene (rare); more indicative of larger 
vessel vasculitis. 
 
Skin vasculitis most common manifestation of rheumatoid 
vasculitis (< 90%). Can also see lower extremity deep 
cutaneous ulcers at malleoli from medium vessel 
vasculitis.  
 
Need to consider other causes, eg thromboembolic 
disease, vasculopathy (systemic sclerosis, buerger’s 
disease), & other forms of vasculitis 
 
 
Slide 
23 Episcleritis
 
25 yo man presents to your clinic with active synovitis 
from RA & this ocular finding. He has slight eye discomfort 
but no real pain. What do you see? What is diagnosis? 
 
Episcleritis is benign cause of red eye & occurs in < 1% 
RA pts. Must be distinguished from more severe causes. 
Need ophthalmology evaluation to eliminate more 
serious conditions. 
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24 Scleritis & Scleromalacia
 
70 yo woman with h/o RA presents with severely painful 
red eyes. What do you see? What is diagnosis? 
 
Scleritis is a serious eye disease, which may result in 
vision loss; may be painless so requires thorough eye 
examination for scleral thinning. EYE EMERGENCY – 
contact ophthalmology immediately. These 2 
conditions occur in < 5% patients with RA but can be very 
serious. 
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25 Sural Nerve Vasculitis
 
75 yo man with inactive RA & tobacco use complains of 1 
week of right foot dragging & 3 days of left hand 
numbness. What is his diagnosis? 
 
Left panel: low power HE showing nerve fiber with vasa 
nervorum. Right panel: high power HE of artery supplying 
the nerve. 
 
Mononeuritis multiplex: characterized by asymmetry, 
asynchrony & predilection for distal nerves. NEUROLOGY 
EVALUATION KEY: diagnose by EMG/NCV & nerve 
biopsy. 
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Neutropenia
Felty’s syndrome
Large granular lymphocytosis
 
Neutropenia may occur by 2 mechanisms. 
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Neutropenia: Felty’s Syndrome
Erosive rheumatoid arthritis
Splenomegaly
Neutropenia 
– Absolute neutrophil count <2000
 
Declining prevalence of Felty’s syndrome over time with 
more effective treatment (<1%). 
 
Seen in setting of long-standing disease, 1/3 pts “burned 
out”. 
 
Clue: high ESR, associated with other extraarticular 
manifestations. 
 
Predisposes to recurrent infections of skin / respiratory 
tract, esp if PMNs <1000, skin ulcers, steroid therapy. 
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28 Neutropenia: Large Granular 
Lymphocyte Syndrome
 
LGLs are a subclass of circulating lymphocytes with 
characteristic granules. May proliferate in RA, causes 
neutropenia +/- splenomegaly. May develop into large 
granular lymphocytic leukemia. Uncommon. 
 
WBCs need to be monitored yearly; if low, repeat with 
differential; refer to hematology for further evaluation – 
will do flow subset analysis, cytogenetics, T cell receptor 
gene studies & bone marrow. 
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29 Nervous System Involvement
 Entrapment neuropathies
– Carpal tunnel syndrome
– Tarsal tunnel syndrome
 Myelopathy from cord compression
 Vasculitic neuropathies
– Distal sensory neuropathy
– Mononeuritis multiplex
 
Increased risk of myelopathy in patients with C1/C2 
subluxation.  
 
Vasculitic peripheral neuropathy has rapid onset; 
characterized by anesthesia > pain; muscle weakness 
may follow. 
 
Always ask about neurologic symptoms & neck pain! 
Do focal neurologic exam, expand as needed. 
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Extraarticular Manifestations
 Typically occur in individuals with 
longstanding disease, high titers of 
RF/anti-CCP, smokers & h/o poorly 
controlled / aggressive disease
 Spectrum of severity
– Benign: nodules, sicca, constitutional, 
nerve entrapments 
– Serious: organizing pneumonia, LGL 
leukemia, myelopathy, vasculitis
 Usually a diagnosis of exclusion
– May need specialty referral
 Need to monitor for Osteoporosis, 
ASVD & muscle weakness
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31 
Review goals and strategies 
for Rheumatoid Arthritis 
treatment
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32 Goals of Therapy
 Prevent disease progression in early 
disease
– Limit functional impairment
– Control symptoms
– Prevent erosive disease
 Preserve and maximize function in 
end-stage disease
 
Choice of therapy depends on severity of disease activity 
when therapy is initiated & response of patient to prior 
therapeutic interventions. 
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33 Strategy to achieve remission or 
low disease activity
 Control inflammation
– Full strength NSAIDs
–Low dose prednisone (10-15 mg qd)
 Initiate disease-modifying antirheumatic 
drug (DMARD) therapy early
 Modify therapy frequently
 Prevent joint pain from injury
– OT/PT referral for splints/ROM
 
Refer patients to Rheumatologist if symptoms present for 
~ 6 weeks (acute arthritis may be viral or reactive & 
resolve spontaneously). Use agents to control 
inflammation but would not initiate DMARD therapy until 
evaluated by rheumatology. Prednisone used as bridge 
therapy & prescribed as burst & taper. NO NEED TO USE 
PREDNISONE 40-60 MG QD! 
 
If synovitis is intermittent (ie pallindromic rheumatism), 
may start hydroxychloroquine (<6.5 mg/kg lean body 
weight). 
 
Earliest treatment has best outcomes (damage may occur 
as early as 6 months). Aim for remission/low disease 
activity by frequent adjustments of medications as 
described in American College of Rheumatology 
guidelines for treatment of RA (Arthritis Care & Research: 
Vol. 64, No. 5, May 2012, pp 625–639). Efficacy & toxicity 
of treatment assessed clinically ~ q3 months. 
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34 First Line Drugs for RA
(traditional/non-biologic DMARDs)
 Methotrexate (MTX)
 Leflunomide [Lef (Arava)]
 Sulfasalazine [SSZ (Azulfadine), 
usually enteric-coated]
 Hydroxychloroquine [HCQ (Plaquenil)]
 May be used singly (for mild, early RA) 
or in combination (for moderate-severe 
or late-onset RA)
 
Methotrexate / leflunomide usually starting drug for all but 
those with mildest RA or contraindications to use (liver 
disease or propensity for liver disease, pregnancy or 
planned, recurrent infections, non-adherence with lab 
testing, renal disease for MTX). Use SSZ or HCQ when 
can’t use 1st  two; often in combination. Monitoring 
guidelines included in Supplementary information. 
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35 Second line drugs for Early RA
(biologic DMARDs)
 Anti-cytokine therapies
– Tumor necrosis factor inhibitors (TNFI)*
– IL-6 receptor antagonist [tocilizumab 
(Actrema)]
 T cell costimulation blocker
– Abatacept [CTLA4-Ig (Orencia)]*
 B-cell depleting therapies
– Rituximab* (Rituxan)
 Janus Kinase inhibitor – inhibits cytokine & 
growth factor signaling
– Tofacitinib (Xeljanz)
* most commonly used biologics
 
All FDA-approved, expensive (most produced by 
recombinant DNA technology) & parenterally – 
administered except for Tofacitinib. 
 
Common TNFI: Enbrel, Humira, Remicade. See 
Supplementary info for more details on composition & 
route of administration 
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 Relatively unique to infusible forms
– Infusion reactions: BP changes, chest pain, 
myalgias, arthralgias, anaphylaxis
 Unique to injectable forms
– Injection site reactions
 Common to all
– Allergic reactions: pruritus, hives
– URI sxs, sinusitis
– SERIOUS INFECTIONS
– TB REACTIVATION esp high risk individuals
– DEMYELINATING Disease 
– Drug-induced autoimmunity
– Decompensation of CHF * many of these are 
common to all biologics  
Watch for these toxicities; especially those capitalized. 
Patients will often present to you with these complaints. 
 
SLE-like syndrome/ANCA-associated vasculitis/psoriasis 
can develop. Tendency to form autoantibodies is more 
common than actual autoimmune disease. These features 
not seen with other biologics (so far). 
 
Cytopenias & hyperlipidemia more common with 
Tocilizumab – so may be asked to monitor lipids more 
closely with this agent. 
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37 Management of RA – this rheumatologist’s approach
 Confirmation of diagnosis clinically
– Based on patient’s clinical features
– Exclude mimickers
 Staging as to whether early or advanced 
disease
 Determine likely prognostic category
– Lab evaluation
• Acute phase reactants
• Rheumatoid factor / anti-CCP
– Radiographs of hands/feet
 
Other causes of chronic, inflammatory polyarthritis need to 
be excluded (SLE & related conditions, hepatitis C, crystal 
or paraneoplastic arthritis).  
 
Staging as to whether early (< 6 months) or late disease is 
obtained by history. 
 
Prognostic evaluation determines course of treatment. 
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38 Management of Early RA
 If RF- or min + and no erosions
– Escalate Methotrexate rapidly to 25 mg 
qwk
– If control isn’t achieved within 3 mos, 
add TNF inhibitor or Sulfasalazine / 
Hydroxychloroquine
– NSAIDs or low dose prednisone for 
symptom control
– OT/PT
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 If significantly RF+ and erosions
– Triple therapy at onset
– TNF inhibitors with Methotrexate or 
Leflunomide
– Low to medium dose prednisone
– OT/PT
 
Triple therapy = methotrexate or leflunomide & 
hydroxychloroquine & sulfasalazine 
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40 Management of Advanced RA
 If active disease, same as for RF+/erosion+
 If inactive “burned-out” disease
– Aggressive OT/PT for deconditioning/loss 
of function
– Surgery for painful and dysfunctional 
joints
– Monitoring for sequelae
• Secondary OA
• Fibromyalgia
• Extraarticular manifestations
– Analgesia for pain control
 
These are the patients that you are more likely to see. You 
need to decide if they have active disease by history and 
exam. If they do, then refer to Rheumatology. If they do 
not, then follow algorithm for inactive disease. 
Slide 
41 KEY POINTS
Overview of Treatment
 Treatment is most effective when 
initiated early
 Single or combination DMARDs are 
mainstay of treatment
 Treatment to target of remission or 
low disease activity is goal
 Monitoring for drug toxicities is 
crucial
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Take Home Points
 RA is a systemic autoimmune disease
 Arthritis of RA is chronic, polyarticular, 
inflammatory & has a characteristic joint 
distribution; atypical presentations occur 
but are less common
 Extraarticular manifestations are common & 
vary from relatively benign to life -
threatening
 Treatment is multidisciplinary & aimed at 
reducing inflammation, preventing joint 
damage, & monitoring for complications of 
disease & drug toxicity
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44 2010 ACR/Eular1 classification criteria 
for RA
 Number & site of joints involved with synovitis2
– 1 point = 2-10 large joints3
– 2 points = 1-3 small joints4
– 3 points = 4-10 small joints
– 5 points = > 10 joints (including > 1 small joint)
 Serological abnormality (RF or anti-CCP)5
– 2 points = low positive (> ULN6)
– 3 points = high positive (> 3 times ULN)
 Elevated ESR or CRP above the ULN = 1 point
 Symptom duration > 6 weeks = 1 point
 Need 6/10 and exclusion of other causes for 
synovitis for definite diagnosis of RA
 
1 Accepted criteria from American College of 
Rheumatology and European League Against 
Rheumatism for individuals with newly presenting arthritis 
(early RA < 6 months).   
 
2 Synovitis = joint swelling associated with tenderness 
 
3 "Large joints" = shoulders, elbows, hips, knees, and 
ankles. 
4 "Small joints" = MCPs, PIPs, 2nd – 5th  MTPs, thumb 
interphalangeal joints, and wrists 
 
5 RF = rheumatoid factor; anti-CCP = antibodies to 
citrullinated proteins 
 
6 ULN = upper limits of normal 
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45 Polyarthritis in RA: Later Disease
 
What joints are involved? 
 
How do you know that this is of longer duration? – atrophy 
of muscles in dorsum of hands and subluxation 
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46 RA: Pathologic Features
 Inflammatory proliferation of 
synovium
 Periarticular osteopenia
 Destruction of cartilage and bone
 Resultant uniform joint space 
narrowing and marginal erosions
 Stretching of periarthritic structures
 Resultant subluxation
 
Autoimmune process occurs in synovium; stimulates 
ingress of inflammatory cells & activates synoviocytes to 
produce mediators of inflammation (cytokines, 
chemokines, etc). These inflammatory molecules are 
responsible for clinical & radiologic features.  
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47 Progression of an Erosion
 
Development of an erosion at a PIP joint of a patient with 
RA. Panel A: fairly normal except for mild soft tissue 
swelling around the joint. Panel B with uniform joint space 
narrowing (solid arrow) and more swelling. Panel C with 
marked joint space narrowing (solid arrow) and marginal 
erosion (dashed arrow). 
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48 TNF Inhibitors (partial list)
 Etanercept (Enbrel)
– Recombinant fusion protein TNF 
receptor and Fc portion of Ig
– Injectable
 Infliximab (Remicade)
– Humanized monoclonal antibody to TNF
– IV infusion
 Adalimumab (Humira)
– Recombinant human antibody to TNF
– Injectable
 
There are other forms too not as commonly used at uihc – 
Certolizumab: human anti-TNF Fab’ linked to polyethylene 
glycol & Golimumab: human anti-TNF 
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49 Rituximab
 Humanized monoclonal antibody to 
CD20
– Deletes B cells
– Minimal effect on humoral immunity
 FDA-approved for RA in TNFI failures
 Given by IV infusion in 2 doses - 2 
weeks apart
 Infusion reactions major adverse 
reaction
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